Recomendaciones y uso de los hipoglucemiantes no insulínicos en los pacientes con insuficiencia cardíaca o eventos cardiovasculares

  1. Álvarez-Rodríguez, Esther
  2. Povar Echevarría, Marina
  3. Martín Sánchez, F. Javier
Revista:
CorSalud

ISSN: 2078-7170

Año de publicación: 2019

Volumen: 11

Número: 2

Páginas: 153-160

Tipo: Artículo

Otras publicaciones en: CorSalud

Repositorio institucional: lock_openAcceso abierto Editor

Resumen

Tanto la diabetes mellitus como la insuficiencia cardíaca son dos enfermedades que frecuentemente van de la mano. Los resultados de recientes estudios sobre disminución de mortalidad, hospitalización por insuficiencia cardíaca y aparición de eventos cardiovasculares, que han demostrado ciertos hipoglucemiantes no insulínicos, han hecho que cambien las recomendaciones en cuanto al tratamiento de la diabetes mellitus. El objetivo clásico del tratamiento de la diabetes, centrado en la reducción de la hemoglobina glicada para reducir el daño microvascular, aunque siga siendo importante, puede que haya pasado a un segundo plano, ahora que disponemos de fármacos que podrían disminuir también el daño macrovascular.

Referencias bibliográficas

  • Parissis JT, Rafouli-Stergiou P, Mebazaa A, Ikonomidis I, Bistola V, Nikolaou M, et al. Acute heart failure in patients with diabetes mellitus: clinical characteristics and predictors of in-hospital mortality. Int J Cardiol. 2012;157(1):108-13.
  • Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006;27(22):2725-36.
  • Greenberg BH, AbrahamWT, AlbertNM, Chiswell K, Clare R, Stough WG, et al. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2007;154(2):277.e1-8.
  • Adams KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149(2):209-16.
  • Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, et al. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry. Am J Cardiol. 1996;77(11):1017-20.
  • Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol. 2003;42(5):914-22.
  • Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(5):853-72.
  • Targher G, Dauriz M, Laroche C, Temporelli PL, Hassanein M, Seferovic PM, et al. In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(1):54-65.
  • Aguirre Tejedo A, Miró O. Prevalencia de factores precipitantes de insuficiencia cardiaca aguda y su impacto pronóstico: una revisión sistemática. Emergencias. 2017;29(3):185-93.
  • Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975.
  • Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017;5(5):333-40.
  • Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-89.
  • Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765-72.
  • Ross S, Gerstein HC, Eikelboom J, Anand SS, Yusuf S, Paré G. Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. Eur Heart J. 2015;36(23):1454-62.
  • Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Khan H, Butterworth AS, Wormser D, et al. Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA. 2014;311(12):1225-33.
  • Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med. 2007;356(24):2457-71.
  • Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125-35.
  • Scirica B, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013;369(14):1317-26.
  • White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med. 2013;369(14):1327-35.
  • Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(3):232-42.
  • Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Díaz R, Dickstein K, et al. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J. 2015;169(5):631-8.
  • Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(13):1228-39.
  • Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann J, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-22.
  • Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-44.
  • Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28.
  • Neal B, Perkovic V, Mahaffey KW, Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-57.
  • Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-57.
  • Cherney DZ, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(8):610-21.
  • Kosiborod M, Cavender M, Norhammar A, Wilding J, Khunti K, Fu AZ, et al. Lower Rates of Hospitalization for Heart Failure and All-Cause Death in New Users of SGLT-2 Inhibitors Versus Other Glucose Lowering Drugs-Real World Data From Six Countries and More Than 300.000 Patients. 66 Annual Scientific Session. Washington DC: American College of Cardiology; 2017.
  • Toulis KA, Willis BH, Marshall T, Kumarendran B, Gokhale K, Ghosh S, et al. All-cause mortality in patients with diabetes under treatment with dapaglifozin: a population-based, open-cohort in THIN database. J Clin Endocrinol Metab. 2017;102(5):1719-25.
  • Cuervo Pinto R, Hernández López S, Aguirre Juaristi N, Chaparro Pardo D, González Armengol JJ, Martín-Sánchez FJ. Efecto de la adecuación al alta del tratamiento antidiabético en los resultados a 90 días en los pacientes ingresados en una unidad de corta estancia. Emergencias. 2018;30(1):14-20.
  • Álvarez-Rodríguez E, Agud M, Caurel Z, Gallego I, Carballo C, Juan A, et al. Recomendaciones de manejo de la diabetes, de sus complicaciones metabólicas agudas y de la hiperglucemia relacionada con corticoides en los servicios de urgencias. Emergencias. 2016;28(6):400-17.
  • Cuervo R, Álvarez-Rodríguez E, González N, Artola-Menéndez S, Girbés J, Mata-Cases M, et al. Documento de consenso sobre el manejo al alta desde Urgencias del paciente diabético. Emergencias. 2017;29(5):343-51.
  • Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319-28.
  • Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-89.
  • Avogaro A, Fadini GP, Sesti G, Bonora E, Del Prato S. Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. Cardiovasc Diabetol [Internet]. 2016 [citado 14 Ene 2019];15(1):111. Disponible en: https://cardiab.biomedcentral.com/track/pdf/10.1186/s12933-016-0431-4